{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:09:25Z","timestamp":1778490565804,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000361","name":"Diabetes UK","doi-asserted-by":"publisher","award":["20\/0006218"],"award-info":[{"award-number":["20\/0006218"]}],"id":[{"id":"10.13039\/501100000361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017645","name":"Moorfields Eye Charity","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100017645","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41433-026-04344-0","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T15:53:28Z","timestamp":1772466808000},"page":"993-998","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive factors for visual acuity in diabetic macular oedema: lessons for clinical practice learned from deferring intravitreal injections under the COVID-19 pandemic"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9914-2775","authenticated-orcid":false,"given":"Marcela","family":"Bohn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Carlo M.","family":"Artiaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5297-2301","authenticated-orcid":false,"given":"Tjebo","family":"Heeren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parth Arvind","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-8368","authenticated-orcid":false,"given":"Marko","family":"Lukic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreenivasa Rao","family":"Kondapally Seshasai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjan","family":"Rajendram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"4344_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S2213-8587(16)30052-3","volume":"5","author":"GS Tan","year":"2017","unstructured":"Tan GS, Cheung N, Sim\u00f3 R, Cheung GCM, Wong TY. Diabetic macular oedema. Lancet Diab Endocrinol. 2017;5:143\u201355.","journal-title":"Lancet Diab Endocrinol"},{"key":"4344_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/dme.14125","volume":"37","author":"OAE Cooper","year":"2020","unstructured":"Cooper OAE, Taylor DJ, Crabb DP, Sim DA, McBain H. Psychological, social and everyday visual impact of diabetic macular oedema and diabetic retinopathy: a systematic review. Diabet Med. 2020;37:924\u201333.","journal-title":"Diabet Med"},{"key":"4344_CR3","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/eye.2013.196","volume":"27","author":"TDL Keenan","year":"2013","unstructured":"Keenan TDL, Johnston RL, Donachie PHJ, Sparrow JM, Stratton IM, Scanlon P. United Kingdom national ophthalmology database study: diabetic retinopathy; report 1: prevalence of centre-involving diabetic macular oedema and other grades of maculopathy and retinopathy in hospital eye services. Eye. 2013;27:1397\u2013404. https:\/\/doi.org\/10.1038\/eye.2013.196.","journal-title":"Eye"},{"key":"4344_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1056\/NEJMra021678","volume":"350","author":"RN Frank","year":"2004","unstructured":"Frank RN. Diabetic retinopathy. N Engl J Med. 2004;350:48\u201358.","journal-title":"N Engl J Med"},{"key":"4344_CR5","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193\u2013203.","journal-title":"N Engl J Med"},{"key":"4344_CR6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0002-9394(14)75794-0","volume":"118","author":"AP Adamis","year":"1994","unstructured":"Adamis AP, Miller JW, Bernal M-T, D\u2019Amico DJ, Folkman J, Yeo T-K, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445\u201350.","journal-title":"Am J Ophthalmol"},{"key":"4344_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185\u2013222.","journal-title":"Ophthalmologica"},{"key":"4344_CR8","doi-asserted-by":"crossref","unstructured":"Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017. https:\/\/doi.wiley.com\/10.1002\/14651858.CD007419.pub5.","DOI":"10.1002\/14651858.CD007419.pub5"},{"key":"4344_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ajo.2019.03.005","volume":"204","author":"TJ Wubben","year":"2019","unstructured":"Wubben TJ, Johnson MW, Sohn EH, Peairs JJ, Kay CN, Kim SJ, et al. Anti\u2013vascular endothelial growth factor therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions. Am J Ophthalmol. 2019;204:13\u20138.","journal-title":"Am J Ophthalmol"},{"key":"4344_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ajo.2018.04.010","volume":"191","author":"NM Holekamp","year":"2018","unstructured":"Holekamp NM, Campbell J, Almony A, Ingraham H, Marks S, Chandwani H, et al. Vision outcomes following anti\u2013vascular endothelial growth factor treatment of diabetic macular edema in clinical practice. Am J Ophthalmol. 2018;191:83\u201391.","journal-title":"Am J Ophthalmol"},{"key":"4344_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ajo.2016.09.002","volume":"172","author":"NV Patrao","year":"2016","unstructured":"Patrao NV, Antao S, Egan C, Omar A, Hamilton R, Hykin PG, et al. Real-World outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom National Health Service setting. Am J Ophthalmol [Internet]. 2016;172:51\u20137.","journal-title":"Am J Ophthalmol [Internet]"},{"key":"4344_CR12","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.ophtha.2015.02.036","volume":"122","author":"R Sophie","year":"2015","unstructured":"Sophie R, Lu N, Campochiaro PA. Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. Ophthalmol. 2015;122:1395\u2013401.","journal-title":"Ophthalmol"},{"key":"4344_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/eye.2013.245","volume":"28","author":"R Channa","year":"2014","unstructured":"Channa R, Sophie R, Khwaja AA, Do DV, Hafiz G, Nguyen QD, et al. Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. Eye. 2014;28:269\u201378.","journal-title":"Eye"},{"key":"4344_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40942-023-00453-0","volume":"9","author":"RL Gurung","year":"2023","unstructured":"Gurung RL, FitzGerald LM, Liu E, McComish BJ, Kaidonis G, Ridge B, et al. Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice. Int J Retina Vitr. 2023;9:23.","journal-title":"Int J Retina Vitr"},{"key":"4344_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40942-022-00380-6","volume":"8","author":"ACS Tan","year":"2022","unstructured":"Tan ACS, Schwartz R, Anaya D, Chatziralli I, Yuan M, Cicinelli MV, et al. Are intravitreal injections essential during the COVID-19 pandemic? Global preferred practice patterns and practical recommendations. Int J Retina Vitr. 2022;8:33.","journal-title":"Int J Retina Vitr"},{"key":"4344_CR16","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00417-020-04703-x","volume":"258","author":"J-F Korobelnik","year":"2020","unstructured":"Korobelnik J-F, Loewenstein A, Eldem B, Joussen AM, Koh A, Lambrou GN, et al. Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. Graefe\u2019s Arch Clin Exp Ophthalmol. 2020;258:1149\u201356.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"4344_CR17","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s00417-021-05549-7","volume":"260","author":"A Navarrete","year":"2022","unstructured":"Navarrete A, Vofo B, Matos K, Rivera A, Chowers I, Levy J. The detrimental effects of delayed intravitreal anti-VEGF therapy for treating retinal pathology: lessons from a forced test case. Graefe\u2019s Arch Clin Exp Ophthalmol. 2022;260:2201\u20138.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"4344_CR18","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.oret.2020.12.020","volume":"5","author":"W Song","year":"2021","unstructured":"Song W, Singh RP, Rachitskaya AV. The effect of delay in care among patients requiring intravitreal injections. Ophthalmol Retina. 2021;5:975\u201380.","journal-title":"Ophthalmol Retina"},{"key":"4344_CR19","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.survophthal.2022.08.002","volume":"67","author":"JHB Im","year":"2022","unstructured":"Im JHB, Jin Y-P, Chow R, Dharia RS, Yan P. Delayed anti-VEGF injections during the COVID-19 pandemic and changes in visual acuity in patients with three common retinal diseases: a systematic review and meta-analysis. Surv Ophthalmol. 2022;67:1593\u2013602.","journal-title":"Surv Ophthalmol"},{"key":"4344_CR20","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/IAE.0000000000003368","volume":"42","author":"J Zarranz-Ventura","year":"2022","unstructured":"Zarranz-Ventura J, Nguyen V, Creuzot-Garcher C, Verbraak F, O\u00b4Toole L, et al. International impact of the COVID-19 pandemic lockdown on intravitreal therapy outcomes. Retina. 2022;42:616\u201327.","journal-title":"Retina"},{"key":"4344_CR21","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s10792-021-01719-y","volume":"41","author":"M Moussa","year":"2021","unstructured":"Moussa M, Elshorbagy MS, Emarah A, Gaber R, Moussa OM, El-Bradey M, et al. Intravitreal injections of anti-VEGF agents during COVID-19 pandemic: clinical audit from Tanta University Hospital. Int Ophthalmol. 2021;41:1437\u201343.","journal-title":"Int Ophthalmol"},{"key":"4344_CR22","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s00417-021-05174-4","volume":"259","author":"LG Stone","year":"2021","unstructured":"Stone LG, Grinton ME, Talks JS. Delayed follow-up of medical retina patients due to COVID-19: impact on disease activity and visual acuity. Graefe\u2019s Arch Clin Exp Ophthalmol. 2021;259:1773\u201380.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"4344_CR23","unstructured":"The National Institute for Health and Care Excellence (NICE). Aflibercept for treating diabetic macular oedema (TA346). 2015."},{"key":"4344_CR24","unstructured":"Programme NDES (DES). Diabetic eye screening: retinal image grading criteria. Available from: https:\/\/www.gov.uk\/government\/publications\/diabetic-eye-screening-retinal-image-grading-criteria"},{"key":"4344_CR25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","volume":"136","author":"NM Bressler","year":"2018","unstructured":"Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, et al. Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment. JAMA Ophthalmol. 2018;136:257.","journal-title":"JAMA Ophthalmol"},{"key":"4344_CR26","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.3390\/jcm11082097","volume":"11","author":"VP Douglas","year":"2022","unstructured":"Douglas VP, Douglas KAA, Vavvas DG, Miller JW, Miller JB. Short- and long-term visual outcomes in patients receiving intravitreal injections: the impact of the coronavirus 2019 disease (COVID-19)\u2014related lockdown. J Clin Med. 2022;11:2097.","journal-title":"J Clin Med"},{"key":"4344_CR27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2147\/OPTH.S289068","volume":"15","author":"M Elfalah","year":"2021","unstructured":"Elfalah M, AlRyalat SA, Toro MD, Rejdak R, Zweifel S, Nazzal R, et al. Delayed intravitreal Anti-VEGF therapy for patients during the COVID-19 lockdown: an ethical endeavor. Clin Ophthalmol. 2021;15:661\u20139.","journal-title":"Clin Ophthalmol"},{"key":"4344_CR28","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.2147\/OPTH.S358239","volume":"16","author":"T Hsieh","year":"2022","unstructured":"Hsieh T, Gundlach BS, Ashrafzadeh S, Sarraf D, Tsui I. Effects of COVID-19 on intravitreal injection clinic after lockdown. Clin Ophthalmol. 2022;16:3089\u201396.","journal-title":"Clin Ophthalmol"},{"key":"4344_CR29","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2019.5790","volume":"321","author":"CW Baker","year":"2019","unstructured":"Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity. JAMA. 2019;321:1880.","journal-title":"JAMA"},{"key":"4344_CR30","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. Ophthalmol. 2016;123:1351\u20139.","journal-title":"Ophthalmol"},{"key":"4344_CR31","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","volume":"127","author":"AR Glassman","year":"2020","unstructured":"Glassman AR, Wells JA, Josic K, Maguire MG, Antoszyk AN, Baker C, et al. Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (protocol T extension study). Ophthalmology. 2020;127:1201\u201310.","journal-title":"Ophthalmology"},{"key":"4344_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102407","volume":"99","author":"A Cvekl","year":"2024","unstructured":"Cvekl A, Vijg J. Aging of the eye: lessons from cataracts and age-related macular degeneration. Ageing Res Rev. 2024;99:102407.","journal-title":"Ageing Res Rev"},{"key":"4344_CR33","first-page":"S67","volume":"19","author":"EK Akpek","year":"2013","unstructured":"Akpek EK, Smith RA. Overview of age-related ocular conditions. Am J Manag Care. 2013;19:S67\u201375.","journal-title":"Am J Manag Care"},{"key":"4344_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.maturitas.2013.01.018","volume":"75","author":"VB Voleti","year":"2013","unstructured":"Voleti VB, Hubschman J-P. Age-related eye disease. Maturitas. 2013;75:29\u201333.","journal-title":"Maturitas"},{"key":"4344_CR35","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.oret.2023.07.015","volume":"7","author":"AJ Yu","year":"2023","unstructured":"Yu AJ, Masalkhi M, Brown R, Chen B, Chhablani J. Racial and ethnic distribution in diabetic macular edema clinical trials in the United States (2002\u20132021). Ophthalmol Retina. 2023;7:1035\u201341.","journal-title":"Ophthalmol Retina"},{"key":"4344_CR36","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.oret.2022.01.018","volume":"6","author":"T Bowe","year":"2022","unstructured":"Bowe T, Salabati M, Soares RR, Huang C, Singh RP, Khan MA, et al. Racial, ethnic, and gender disparities in diabetic macular edema clinical trials. Ophthalmol Retina. 2022;6:531\u20133.","journal-title":"Ophthalmol Retina"},{"key":"4344_CR37","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jamaophthalmol.2021.0857","volume":"139","author":"ST Berkowitz","year":"2021","unstructured":"Berkowitz ST, Groth SL, Gangaputra S, Patel S. Racial\/Ethnic disparities in ophthalmology clinical trials resulting in US Food and Drug Administration drug approvals from 2000 to 2020. JAMA Ophthalmol. 2021;139:629.","journal-title":"JAMA Ophthalmol"},{"key":"4344_CR38","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamaophthalmol.2018.6786","volume":"137","author":"SB Bressler","year":"2019","unstructured":"Bressler SB, Odia I, Maguire MG, Dhoot DS, Glassman AR, Jampol LM, et al. Factors associated with visual acuity and central subfield thickness changes when treating diabetic macular edema with anti\u2013vascular endothelial growth factor therapy. JAMA Ophthalmol. 2019;137:382.","journal-title":"JAMA Ophthalmol"},{"key":"4344_CR39","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ajo.2020.09.042","volume":"222","author":"P Osathanugrah","year":"2021","unstructured":"Osathanugrah P, Sanjiv N, Siegel NH, Ness S, Chen X, Subramanian ML. The impact of race on short-term treatment response to bevacizumab in diabetic macular edema. Am J Ophthalmol. 2021;222:310\u20137.","journal-title":"Am J Ophthalmol"},{"key":"4344_CR40","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/dme.13895","volume":"36","author":"LM Goff","year":"2019","unstructured":"Goff LM. Ethnicity and type 2 diabetes in the <scp>UK<\/scp>. Diabet Med. 2019;36:927\u201338.","journal-title":"Diabet Med"},{"key":"4344_CR41","doi-asserted-by":"crossref","unstructured":"Sivaprasad S, Gupta B, Gulliford MC, Dodhia H, Mohamed M, Nagi D, et al. Ethnic variations in the prevalence of diabetic retinopathy in people with diabetes attending screening in the United Kingdom (DRIVE UK). PLoS ONE. 2012;7:e32182. Available from: https:\/\/dx.plos.org\/10.1371\/journal.pone.0032182","DOI":"10.1371\/journal.pone.0032182"},{"key":"4344_CR42","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JWY Yau","year":"2012","unstructured":"Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556\u201364.","journal-title":"Diabetes Care"},{"key":"4344_CR43","doi-asserted-by":"publisher","first-page":"1096.","DOI":"10.1001\/jamaophthalmol.2022.3929","volume":"140","author":"A-H Kaakour","year":"2022","unstructured":"Kaakour A-H, Hua H-U, Rachitskaya A. Representation of Race and Ethnicity in Randomized Clinical Trials of Diabetic Macular Edema and Retinal Vein Occlusion Compared to 2010 US Census Data. JAMA Ophthalmol. 2022;140:1096.","journal-title":"JAMA Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04344-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04344-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04344-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:29:15Z","timestamp":1778488155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04344-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4344"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04344-0","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}